Pharmacodynamic Evaluation of Irinotecan Therapy by FDG and FLT PET/CT Imaging in a Colorectal Cancer Xenograft Model
Sarah R. Mudd(AbbVie (United States)), Yanping Luo(Abbott Fund), Kimberley D. Holich(Abbott (United States)), Joann P. Palma(Abbott Fund), David R. Reuter(AbbVie (United States)), Mark L. Day(Royal Society for the Protection of Birds), Cherrie K. Donawho(Abbott Fund), Gail Bukofzer(Institute of Cancer Research), Todd Cole(AbbVie (United States)), Gerard B. Fox(Purdue University West Lafayette), Arunava Chakravartty(National Cancer Center), Paul Tapang(AbbVie (United States)), Martin J. Voorbach(AbbVie (United States))
Cited by 19
Related Papers
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776
Validation of Diacyl Glycerolacyltransferase I as a Novel Target for the Treatment of Obesity and Dyslipidemia Using a Potent and Selective Small Molecule Inhibitor
|Journal of Medicinal Chemistry|2008|140
A quantitation method for mass spectrometry imaging
|Rapid Communications in Mass Spectrometry|2011|92
Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody
|Molecular Cancer Therapeutics|2015|83